Conference Report: 4th Global CRO Council for Bioanalysis: Coadministered drugs stability, EMA/US FDA Guidelines, 483s and Carryover

Bioanalysis

Volumn 4, Issue 7, 2012, Pages 763-768

  Lowes, Steve ^a   Jersey, Jim ^b   Shoup, Ronald ^c   Garofolo, Fabio ^d   Needham, Shane ^e   Couerbe, Philippe ^f   Lansing, Tim ^g   Bhatti, Masood ^h   Sheldon, Curtis ⁱ   Hayes, Roger ^j,s   Islam, Rafiq ^k   Lin, Zhongping ^l   Garofolo, Wei ^m   Moussallie, Marc ⁿ   Teixeira, Leonardo De Souza ^o   Rocha, Thais ^o   Jardieu, Paula ^p   Truog, James ^q   Lin, Jenny ^q   Lundberg, Richard ^r   Breau, Alan ^s   Dilger, Carmen ^t   Bouhajib, Mohammed ^u   Levesque, Ann ^v   Gagnon Carignan, Sofi ^v   Jenkins, Rand ^w   Nicholson, Robert ^w   Lin, Ming Hung ^q   Karnik, Shane ^x   DeMaio, William ^y   Smith, Kirk ^z   Cojocaru, Laura ^aa   Allen, Mike ^ab   Fatmi, Saadya ^ac   Sayyarpour, Farhad ^ad   Malone, Michele ^ae   Fang, Xinping ^af   more..

^a Advion BioSciences Inc   (United States)

^b Agilux Laboratories   (United States)

^c AIT Bioscience   (United States)

^d Algorithme Pharma   (Canada)

^e Alturas Analytics   (United States)

^f SOLVO BIOTECHNOLOGY   (Hungary)

^g BioAgilytix Labs   (United States)

^h BioPharma Services   (Canada)

ⁱ CELERION   (United States)

^j Cetero Research   (United States)

^k EMD Millipore   (United States)

^l Frontage Laboratories   (United States)

^m Global CRO Council for Bioanalysis (GCC)   (Canada)

ⁿ Huntingdon Life Sciences New Jersey   (United States)

^o ICF   (Brazil)

^p ICON Development Solutions   (United States)

^q JCL Bioassay USA ^*  (Taiwan)

^r MEDTOX Laboratories   (United States)

^s MPI RESEARCH   (United States)

^t Nuvisan GmbH   (Germany)

^u Pharma Medica   (Canada)

^v PharmaNet Canada   (Canada)

^w Pharmaceutical Product Development   (United States)

^x Pyxant Labs   (United States)

^y Ricerca Inc   (United States)

^z Smithers Viscient   (United States)

^aa Tandem Labs   (United States)

^ab Tandem Labs   (United States)

^ac Warnex Bioanalytical   (Canada)

^ad WIL Research Company   (United States)

^ae Worldwide Clinical Trials   (United States)

^af XENOBIOTIC LABORATORIES INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTIC METHOD; BIOEQUIVALENCE; CALIBRATION; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DRUG FORMULATION; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; FREEZE THAWING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PRACTICE GUIDELINE; QUALITY CONTROL; REFERENCE VALUE; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; ANALYSIS; CHEMICAL ANALYSIS; CHEMISTRY; DOCUMENTATION; DRUG COMBINATION; EUROPE; NON PROFIT ORGANIZATION; NOTE; REPRODUCIBILITY; STANDARD; UNITED STATES;

ANALYTIC SAMPLE PREPARATION METHODS; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; DOCUMENTATION; DRUG COMBINATIONS; DRUG STABILITY; EUROPE; GUIDELINES AS TOPIC; ORGANIZATIONS, NONPROFIT; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84859984284     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.48     Document Type: Conference Paper

References (12)

1. Premkumar N, Lowes S, Jersey J et al. Formation of a Global Contract Research Organization Council for bioanalysis. Bioanalysis 2(11), 1797-1800 (2010).
2. Dumont I, Garofolo F. Conference report: the 1st conference in Asia-Pacific on recent issues in bioanalysis. Bioanalysis 3(7), 723-731 (2011).
3. Breda M. Garofolo F, Caturla MC et al. The 3rd Global CRO Council (GCC) for Bioanalyis at the International Reid Bioanalytical Forum. Bioanalysis 3(24), 2721-2727 (2011).
4. Savoie N, Garofolo F, van Amsterdam P et al. 2010 White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis 2(12), 1945-1960 (2010).
5. Garofolo F, Rocci ML, Dumont I et al. 2011 White Paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis 3(18), 2081-2096 (2011).
6. Lowes S, Jersey J, Shoup R et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for bioanalysis. Bioanalysis 3(12), 1323-1332 (2011).
7. European Medicines Agency. Guideline on bioanalytical method validation. European Medcines Agency, Committee for Proprietary Medicinal Products (CPMP), London, UK (2011).
8. US FDA. Guidance for Industry: bioanalytical method validation. US FDA, Center for Drug Evaluation and Research, MD, USA (2001).
9. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Workshop/Conference Report. AAPS J. 9(1), E30-E42 (2007).
10. ANVISA. Manual for Good Bioavailability and Bioequivalence Practices. Brazilian Sanitary Surveillance Agency, Brazil (2002).
11. Boterman M, Doig M, Breda M et al. Recommendations on the Interpretation of the new European Medicines Agency Guideline on bioanalytical method validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis (In press).
12. USP. Shipping Conditions for USP Reference Standards. USP, Rockville, MA, USA (2008).